Equities research analysts forecast that TESARO, Inc. (NASDAQ:TSRO) will report earnings per share (EPS) of ($1.19) for the current quarter, according to Zacks. Seven analysts have provided estimates for TESARO’s earnings. The lowest EPS estimate is ($2.57) and the highest is ($0.52). TESARO posted earnings of ($1.98) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 39.9%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 2nd.
On average, analysts expect that TESARO will report full year earnings of ($9.00) per share for the current year, with EPS estimates ranging from ($10.60) to ($8.04). For the next year, analysts expect that the business will report earnings of ($5.07) per share, with EPS estimates ranging from ($7.63) to ($0.57). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover TESARO.
TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same period in the previous year, the company earned ($1.28) EPS. TESARO’s revenue was down 17.6% on a year-over-year basis.
Several brokerages have recently commented on TSRO. Royal Bank Of Canada started coverage on shares of TESARO in a research note on Thursday, September 14th. They set a “sector perform” rating and a $120.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of TESARO in a research note on Monday, September 11th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $199.00 price objective on shares of TESARO in a report on Sunday, September 10th. Citigroup Inc. reiterated a “buy” rating and issued a $216.00 price objective on shares of TESARO in a report on Monday, September 11th. Finally, Cann reissued a “buy” rating and set a $199.00 target price on shares of TESARO in a research report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. TESARO currently has an average rating of “Buy” and an average target price of $171.42.
In related news, VP Grant C. Bogle sold 14,167 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Edward C. English sold 10,862 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,692 shares of company stock worth $4,628,976. Insiders own 40.50% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its stake in TESARO by 5.7% during the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after acquiring an additional 195,590 shares during the period. Vanguard Group Inc. raised its holdings in TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after acquiring an additional 62,104 shares in the last quarter. State Street Corp lifted its position in shares of TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after acquiring an additional 177,057 shares during the period. BB Biotech AG lifted its position in shares of TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after acquiring an additional 53,408 shares during the period. Finally, Janus Henderson Group PLC bought a new stake in shares of TESARO in the 2nd quarter worth approximately $100,301,000.
TESARO (TSRO) traded up 4.36% during trading on Friday, hitting $129.10. 754,930 shares of the company traded hands. The firm’s market cap is $6.99 billion. The firm has a 50 day moving average of $121.03 and a 200 day moving average of $138.94. TESARO has a one year low of $96.52 and a one year high of $192.94.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.